PARP Combination Therapies in Ovarian Cancer

From Lab to Life: Medicinal Chemistry Behind PARP-1 Inhibitors!👩‍🔬💊📚Подробнее

What are PARP Inhibitors?Подробнее

Future Forward Therapies in Ovarcoming Ovarian CancerПодробнее

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ov...Подробнее

Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combination...Подробнее

Prostate Cancer | Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor...Подробнее

Identifying optimal patient subgroups in ovarian cancer for neoadjuvant PARP inhibitor therapyПодробнее

Advancing Therapeutic Paradigms for Ovarian Cancer in The Era of PARP Inhibitors: A Guide for The...Подробнее

Evaluating future use of PARP inhibitors in neoadjuvant therapy for ovarian cancerПодробнее

What are my options after PARP inhibitor and immunotherapy?Подробнее

Debate Part 1: mCRPC PARP Inhibitor Monotherapy, Combined With AR-targeting Agents, and MoreПодробнее

Uromigos Live 2023: Where Do We Stand With PARP Inhibitors in Prostate Cancer?Подробнее

JAVELIN PARP Medley: Combining PARP inhibitors and immune checkpoint inhibitorsПодробнее

PLGA-PEG-Dibenzocyclooctyne from PolySciTech used in research on PARPi treatment for ovarian cancer.Подробнее

Knowing Your Way - Maintenance TherapyПодробнее

Allarity's Stenoparib - A Next Generation PARP InhibitorПодробнее

PARP inhibitor treatment in non-BRCA mutant high-grade serous ovarian cancer – Dr. Nicola HannawayПодробнее

PARP Inhibitors simplifiedПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее